CLL
MCID: LKM071
MIFTS: 74

Leukemia, Chronic Lymphocytic (CLL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Chronic Lymphocytic

MalaCards integrated aliases for Leukemia, Chronic Lymphocytic:

Name: Leukemia, Chronic Lymphocytic 57 72 37 39
Chronic Lymphocytic Leukemia 12 73 20 36 29 6 42 15 17 70
B-Cell Chronic Lymphocytic Leukemia 12 58 72
Cll 57 12 72
B-Cell Chronic Lymphoid Leukemia 12 58
Chronic Lymphocytic Leukaemia 12 15
Chronic Lymphatic Leukemia 12 72
Lymphoplasmacytic Leukemia 12 70
Small Lymphocytic Lymphoma 58 70
Leukemia, Lymphocytic, Chronic, B-Cell 44
B-Cell Chronic Lymphocytic Leukaemia 12
B Cell Chronic Lymphocytic Leukemia 20
Chronic B-Cell Lymphocytic Leukemia 20
Leukemia, Lymphocytic, Chronic 20
Leukemia Lymphocytic Chronic 54
Leukemia, Chronic Lymphatic 57
Chronic Lymphatic Leukaemia 12
Lymphoplasmacytic Leukaemia 12
Lymphoma Small Lymphocytic 54
Chronic Lymphoid Leukemia 72
B-Cll 58

Characteristics:

Orphanet epidemiological data:

58
b-cell chronic lymphocytic leukemia
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: Adult;

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
somatic mutation
autosomal dominant

Miscellaneous:
associated with susceptibility loci on chromosome 11p11 (clls1, ), 13q14 (clls2, ), 9q34.1 (clls3, ), 6p25.3 (clls4, ), and 11q24.1 (clls5, )


HPO:

31
leukemia, chronic lymphocytic:
Inheritance somatic mutation autosomal dominant somatic cell mutation


Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:1040
OMIM® 57 151400
KEGG 36 H00005
ICD9CM 34 204.1
MeSH 44 D015451
NCIt 50 C3163
SNOMED-CT 67 51092000
ICD10 32 C91.10
MESH via Orphanet 45 D015451
ICD10 via Orphanet 33 C91.1
UMLS via Orphanet 71 C0023434 C0855095 C1868683
Orphanet 58 ORPHA67038
MedGen 41 C0023434
SNOMED-CT via HPO 68 124975008 277473004 92814006
UMLS 70 C0023434 C0855095 C2854089

Summaries for Leukemia, Chronic Lymphocytic

MedlinePlus : 42 What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What is chronic lymphocytic leukemia (CLL)? Chronic lymphocytic leukemia (CLL) is a type of chronic leukemia. "Chronic" means that the leukemia usually gets worse slowly. In CLL, the bone marrow makes abnormal lymphocytes (a type of white blood cell). When the abnormal cells crowd out the healthy cells, it can lead to infection, anemia, and easy bleeding. The abnormal cells can also spread outside the blood to other parts of the body. CLL is one of the most common types of leukemia in adults. It often occurs during or after middle age. It is rare in children. What causes chronic lymphocytic leukemia (CLL)? CLL happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown, so it's hard to predict who might get CLL. There are a few factors that might raise your risk. Who is at risk for chronic lymphocytic leukemia (CLL)? It is hard to predict who will get CLL. There are a few factors that could raise your risk: Age - your risk goes up as you get older. Most people who are diagnosed with CLL are over 50. Family history of CLL and other blood and bone marrow diseases Racial/ethnic group - CLL is more common in whites than in people from other racial or ethnic groups Exposure to certain chemicals, including Agent Orange, a chemical that was used in the Vietnam War What are the symptoms of chronic lymphocytic leukemia (CLL)? The signs and symptoms of CLL include Swollen lymph nodes - you may notice them as painless lumps in the neck, underarm, stomach, or groin Weakness or feeling tired Pain or a feeling of fullness below the ribs Fever and infection Easy bruising or bleeding Petechiae, which are tiny red dots under the skin. They are caused by bleeding. Weight loss for no known reason Drenching night sweats How is chronic lymphocytic leukemia (CLL) diagnosed? Your health care provider may use many tools to diagnose CLL: A physical exam A medical history Blood tests, such as a complete blood count (CBC) with differential and blood chemistry tests. Blood chemistry tests measure different substances in the blood, including electrolytes, fats, proteins, glucose (sugar), and enzymes. Specific blood chemistry tests include a basic metabolic panel (BMP), a comprehensive metabolic panel (CMP), kidney function tests, liver function tests, and an electrolyte panel. Flow cytometry tests, which check for leukemia cells and identify which type of leukemia it is. The tests can be done on blood, bone marrow, or other tissue. Genetic tests to look for gene and chromosome changes If you are diagnosed with CLL, you may have additional tests to see whether the cancer has spread. These include imaging tests and bone marrow tests. What are the treatments for chronic lymphocytic leukemia (CLL)? Treatments for CLL include Watchful waiting, which means that you don't get treatment right away. Your health care provider regularly checks to see if your signs or symptoms appear or change. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Chemotherapy Radiation therapy Immunotherapy Chemotherapy with bone marrow or stem cell transplant The goals of treatment are to slow the growth of the leukemia cells and to give you long periods of remission. Remission means that the signs and symptoms of cancer are reduced or have disappeared. The CLL may come back after remission, and you may need more treatment. NIH: National Cancer Institute

MalaCards based summary : Leukemia, Chronic Lymphocytic, also known as chronic lymphocytic leukemia, is related to cll/sll and lung cancer, and has symptoms including fatigue, angina pectoris and chest pain. An important gene associated with Leukemia, Chronic Lymphocytic is MIR15A (MicroRNA 15a), and among its related pathways/superpathways are DNA Damage Response and MicroRNAs in cancer. The drugs Valganciclovir and Venetoclax have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are cellular immunodeficiency and chronic lymphatic leukemia

Disease Ontology : 12 A lymphocytic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood.

GARD : 20 Chronic lymphocytic leukemia (CLL) is a type of cancer of the white blood cells ( lymphocytes ). Early signs and symptoms may include swollen lymph nodes, fatigue, weight loss, fever, night sweats and/or frequent infections. CLL usually occurs in adults around the age of 70 and begins in the bone marrow and then spreads to the blood. Over time, CLL may also spread to the lymph nodes and other organs, including the liver, spleen and lungs. The severity and outcome of CLL depends on many factors. The underlying cause is thought to be a combination of genetic and other unknown factors. It usually occurs in people with no family history of the condition, but familial cases have been reported. CLL is diagnosed based on the symptoms and various blood tests. Treatment options depend on many factors, including the stage of the condition, blood cell counts, and whether the CLL has recurred (come back).

OMIM® : 57 Chronic lymphocytic leukemia (CLL) is a common neoplasia of B lymphocytes in which these cells progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival (summary by Quesada et al., 2012). (151400) (Updated 05-Apr-2021)

KEGG : 36 Chronic lymphocytic leukemia (CLL) is caused by the abnormal progressive accumulation of functionally incompetent monoclonal B-lymphocytes in blood, bone marrow, lymph nodes and spleen. It is the most common adult leukemia in Western countries, accounting for about 30% of total leukaemias. Worldwide there are approximately 180,000 new cases every year. A main focus in CLL research involved the evaluation of genetic features related to somatic gene mutation or deletions that disrupt apoptosis and enhance tumor cell proliferation. The best characterized genes are TP53 (also known as p53) and ATM, for which mutations and/or deletions have been described that predict rapid disease progression, resistance to conventional therapies and poor survival.

UniProtKB/Swiss-Prot : 72 Leukemia, chronic lymphocytic: A chronic leukemia in which functionally incompetent B-lymphocytes progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival.

Wikipedia : 73 Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many... more...

Related Diseases for Leukemia, Chronic Lymphocytic

Diseases in the Leukemia, Chronic Lymphocytic family:

Leukemia, Chronic Lymphocytic 2 Leukemia, Chronic Lymphocytic 1
Leukemia, Chronic Lymphocytic 3 Leukemia, Chronic Lymphocytic 4
Leukemia, Chronic Lymphocytic 5 Adult Acute Lymphocytic Leukemia

Diseases related to Leukemia, Chronic Lymphocytic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1092)
# Related Disease Score Top Affiliating Genes
1 cll/sll 32.9 TP53 CCND1 ATM
2 lung cancer 32.3 TP53COR1 TP53 MIR424 MIR34A MIR29A MIR16-1
3 renal cell carcinoma, nonpapillary 32.2 TP53 MIR424 MIR34A MIR15A MIR145 MIR143
4 prostate cancer 32.1 TP53COR1 TP53 MIR34A MIR29A MIR16-1 MIR15A
5 b-cell lymphoma 32.1 TP53COR1 TP53 MIR34A CCND1 ATM
6 lymphoma, non-hodgkin, familial 31.9 TP53 MIR424 MIR34A MIR15A MIR143 CCND1
7 mantle cell lymphoma 31.8 TP53 MIR16-1 DLEU2 CCND1 ATM
8 hepatocellular carcinoma 31.8 TP53COR1 TP53 MIR424 MIR34A MIR29A MIR181A2
9 diffuse large b-cell lymphoma 31.8 TP53 MIR145 MIR143 CCND1
10 myeloma, multiple 31.8 TP53 MIR181A2 MIR15A MIR145 MIR106B IKZF3
11 leukemia, acute myeloid 31.7 TP53 MIR424 MIR34A MIR29A MIR181A2 MIR15A
12 kidney cancer 31.6 TP53 MIR424 MIR29A MIR15A MIR106B
13 cervical cancer 31.5 TP53COR1 TP53 MIR34A MIR15A MIR145 MIR143
14 burkitt lymphoma 31.5 TP53COR1 TP53 MIR29A MIR145 MIR143 DLEU1
15 prolymphocytic leukemia 31.5 TP53 CCND1 ATM
16 esophageal cancer 31.5 TP53 MIR34A MIR145 MIR143 MIR107 CCND1
17 larynx cancer 31.5 TP53 MIR34A MIR143 MIR106B DLEU2 CCND1
18 squamous cell carcinoma, head and neck 31.4 TP53 MIR424 MIR15A MIR145 MIR143 CCND1
19 connective tissue disease 31.4 TP53 MIR34A MIR29A MIR145 MIR143
20 gastric cancer 31.4 TP53COR1 TP53 MIR34A MIR16-1 MIR145 MIR143
21 nervous system disease 31.4 TP53 MIR424 MIR34A MIR29A MIR15A MIR145
22 glioma 31.3 TP53COR1 TP53 POT1 MIR34A MIR181A2 MIR15A
23 hematologic cancer 31.3 MIR424 MIR34A MIR29A MIR16-1 MIR15A MIR145
24 oral squamous cell carcinoma 31.3 TP53 MIR34A MIR29A MIR145 MIR143 MIR107
25 rectum cancer 31.3 MIR424 MIR29A MIR145 MIR143
26 chromosome 13q14 deletion syndrome 31.3 TP53 MIR15A ATM
27 melanoma, cutaneous malignant 1 31.3 TP53 POT1 CCND1 ATM
28 central nervous system disease 31.2 MIR34A MIR29A MIR15A MIR145 MIR143 MIR106B
29 melanoma 31.2 TP53 POT1 MIR34A MIR181A2 MIR15A MIR107
30 bone marrow cancer 31.0 TP53 MIR34A MIR145 CCND1
31 aortic valve disease 2 31.0 MIR424 MIR34A MIR106B
32 dyskeratosis congenita 31.0 TP53 RPS15 POT1 ATM
33 in situ carcinoma 30.9 TP53 MIR143 CCND1
34 colorectal adenocarcinoma 30.8 TP53 CCND1 ATM
35 clear cell renal cell carcinoma 30.6 TP53 MIR145 MIR106B CCND1
36 leukemia, chronic lymphocytic 2 11.6
37 leukemia, chronic lymphocytic 4 11.6
38 leukemia, chronic lymphocytic 5 11.6
39 leukemia, chronic lymphocytic 1 11.5
40 leukemia, chronic lymphocytic 3 11.5
41 richter's syndrome 11.3
42 leukemia 11.2
43 pancreatic cancer 11.2 TP53 MIR424 MIR34A MIR181A2 MIR16-1 MIR15A
44 immunotactoid glomerulopathy 11.2
45 immunotactoid or fibrillary glomerulopathy 11.2
46 lymphatic system cancer 11.1 TP53 MIR424 MIR34A MIR29A MIR16-1 MIR15A
47 lymphatic system disease 11.1 TP53 MIR424 MIR34A MIR29A MIR16-1 MIR15A
48 respiratory system disease 11.1 TP53 MIR424 MIR34A MIR29A MIR16-1 MIR15A
49 intestinal disease 11.0 TP53 MIR424 MIR34A MIR29A MIR15A MIR145
50 cervix disease 11.0 TP53 MIR34A MIR29A MIR15A MIR145 MIR143

Comorbidity relations with Leukemia, Chronic Lymphocytic via Phenotypic Disease Network (PDN): (show all 12)


Acquired Thrombocytopenia Acute Cystitis
Agammaglobulinemia, X-Linked Anemia, Autoimmune Hemolytic
Bronchitis Chronic Leukemia
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1
Leukemia Neutropenia

Graphical network of the top 20 diseases related to Leukemia, Chronic Lymphocytic:



Diseases related to Leukemia, Chronic Lymphocytic

Symptoms & Phenotypes for Leukemia, Chronic Lymphocytic

Human phenotypes related to Leukemia, Chronic Lymphocytic:

31
# Description HPO Frequency HPO Source Accession
1 cellular immunodeficiency 31 HP:0005374
2 chronic lymphatic leukemia 31 HP:0005550

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Hematology:
chronic lymphatic leukemia

Laboratory Abnormalities:
recurring t(11,14) and t(14,19)(q32,q13.1) translocations

Immunology:
impaired cellular and humoral immunity

Clinical features from OMIM®:

151400 (Updated 05-Apr-2021)

UMLS symptoms related to Leukemia, Chronic Lymphocytic:


fatigue; angina pectoris; chest pain; edema

Drugs & Therapeutics for Leukemia, Chronic Lymphocytic

Drugs for Leukemia, Chronic Lymphocytic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 436)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
2
Venetoclax Approved, Investigational Phase 4 1257044-40-8 49846579
3
Chlorambucil Approved Phase 4 305-03-3 2708
4 Antineoplastic Agents, Hormonal Phase 4
5 Epoetin alfa Phase 4 113427-24-0
6 Hematinics Phase 4
7
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
8
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
9
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
10
Zanubrutinib Approved, Investigational Phase 3 1691249-45-2
11
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
12
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
13
tannic acid Approved Phase 3 1401-55-4
14
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
15
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
16
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
17
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
18
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
19
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
20
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
21
Fexofenadine Approved, Investigational Phase 3 83799-24-0 3348
22
Ocrelizumab Approved, Investigational Phase 3 637334-45-3
23
Lenograstim Approved, Investigational Phase 3 135968-09-1
24
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
25
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
26
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221
27
Tenofovir Experimental, Investigational Phase 3 147127-20-6 464205
28
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
29 Ferric Oxide, Saccharated Phase 3
30 Anti-Infective Agents Phase 3
31 Antiviral Agents Phase 3
32 Anti-Retroviral Agents Phase 3
33 Anti-HIV Agents Phase 3
34 Reverse Transcriptase Inhibitors Phase 3
35 triamcinolone acetonide Phase 3
36 Triamcinolone diacetate Phase 3
37 Triamcinolone hexacetonide Phase 3
38 Antibodies, Monoclonal Phase 3
39 Neurotransmitter Agents Phase 3
40 Gastrointestinal Agents Phase 3
41 Antiemetics Phase 3
42 Hormones Phase 3
43 Immunoglobulins, Intravenous Phase 3
44 Neuroprotective Agents Phase 3
45 Methylprednisolone Acetate Phase 3
46 Hormone Antagonists Phase 3
47 glucocorticoids Phase 3
48 Anti-Inflammatory Agents Phase 3
49 Protective Agents Phase 3
50 Histamine H1 Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 1376)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
2 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Unknown status NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
3 A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
4 Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study Completed NCT01255644 Phase 4 Valganciclovir
5 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
6 A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
7 A Single-arm, International, Multi-center Trial Investigating the Efficacy and Safety of Ofatumumab Retreatment and Maintenance in CLL Patients Who Progressed Following Response or Stable Disease After Ofatumumab Treatment in Hx-CD20-406 Completed NCT00802737 Phase 4 Ofatumumab
8 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
9 A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
10 Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens Not yet recruiting NCT04790045 Phase 4 Venetoclax
11 Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status Terminated NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
12 Prospective Randomized Study to Compare Efficacy and Safety of RFC-Lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status Terminated NCT01283386 Phase 4 Chlorambucil;Cyclophosphamide;Fludarabine;Rituximab
13 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
14 Combination of Ibrutinib and As2O3 in the Treatment of CLL Unknown status NCT02757040 Phase 3 Ibrutinib combined with As2O3;ibrutinib
15 Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3 FFP+HDMP+Rituximab
16 A Randomised Investigation of Alternative Ofatumumab-containing Regimens in Less Fit Patients With CLL Unknown status NCT01678430 Phase 3 Ofatumumab;Chlorambucil;Bendamustine
17 Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients Unknown status NCT01657955 Phase 3 Bendamustine Hydrochloride Injection;Chlorambucil
18 Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3) Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
19 A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia Completed NCT00254163 Phase 3 Fludarabine;Cyclophosphamide;Rituximab;Pentostatin
20 A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
21 A Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-Line Therapy With Fludarabine Plus Alemtuzumab vs. Fludarabine Alone in Patients With B-Cell Chronic Lymphocytic Leukemia Completed NCT00086580 Phase 3
22 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial) Completed NCT00774345 Phase 3 Lenalidomide;Placebo
23 A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial) Completed NCT00910910 Phase 3 Lenalidomide;Chlorambucil
24 A Randomized, Open Label Study to Assess the Effect of Maintenance Treatment With Mabthera (Rituximab) Versus No Treatment, After Induction Treatment With Rituximab, Cladribine and Cyclophosphamide (RCC) on Progression-Free Survival in Previously Untreated Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00718549 Phase 3 Cladribine;Cyclophosphamide;Rituximab
25 A Prospective Case Series of Subcutaneous Immunoglobulin for Prophylaxis of Infections in Patients With Chronic Lymphocytic Leukemia With Impaired Humoral Immunity Completed NCT03730129 Phase 2, Phase 3 Hizentra
26 Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia Completed NCT00769522 Phase 3 Bendamustine;Cyclophosphamide;Fludarabine
27 A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT02264574 Phase 3 Ibrutinib;Obinutuzumab;Chlorambucil
28 Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01722487 Phase 3 Ibrutinib;Chlorambucil
29 A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
30 Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01611090 Phase 3 Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
31 A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01578707 Phase 3 ofatumumab;ibrutinib
32 A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07 Completed NCT02049515 Phase 3 IPI-145 (duvelisib);Ofatumumab
33 Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia Completed NCT00281918 Phase 3 Rituximab;Cyclophosphamide;Fludarabine Phosphate
34 An Open Label, Multicenter Study Investigating the Safety and Efficacy of Ofatumumab Therapy Versus Physicians' Choice in Patients With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukaemia (CLL) Completed NCT01313689 Phase 3 Ofatumumab;Physicians' Choice
35 Fludarabine Versus Chlorambucil in First Line Therapy of Elderly Patients (More Than 65 Years) With Advanced Chronic Lymphocytic Leukemia Completed NCT00262795 Phase 3 Fludarabine;Chlorambucil
36 Open-label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of FCR vs. FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL Completed NCT00090051 Phase 3 Rituximab;Fludarabine Phosphate;Cyclophosphamide
37 International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia Completed NCT01118234 Phase 3 Rituximab
38 Randomized Phase III Trial Comparing Early Treatment With Fludarabine/Cyclophosphamide + Rituximab Versus Deferred Treatment in Untreated Binet Stage A Patients With CLL and High Risk of Progression Completed NCT00275054 Phase 3 Fludarabine;Cyclophosphamide
39 A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia Completed NCT01905943 Phase 3 Bendamustine;Chlorambucil;Cyclophosphamide;Fludarabine;Obinutuzumab
40 A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) Completed NCT02301156 Phase 3 Ublituximab;ibrutinib
41 Fludarabine Versus Fludarabine Plus Cyclophosphamide in First Line Therapy of Younger Patients (Up to 65 Years) With Advanced Chronic Lymphocytic Leukemia (CLL) Completed NCT00276848 Phase 3 Fludarabine plus Cyclophosphamide;Fludarabine
42 Darbepoetin Alfa in Patients With Chronic Lymphocytic Leukemia and Comorbidity Completed NCT00281892 Phase 3 Fludarabine mono
43 A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia Completed NCT01892618 Phase 3 Prevenar 13;Pneumovax
44 A Pilot Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) Completed NCT02801578 Phase 2, Phase 3 Ibrutinib
45 Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
46 Bendamustine Versus Fludarabine as 2nd-line Treatment in Chronic Lymphocytic Leukemia, Stage BINET B+C / RAI II-IV Completed NCT01423032 Phase 2, Phase 3 bendamustine;Fludarabine
47 Randomized Phase III Trial Evaluating the Role of Autologous Stem Cell Transplantation in Previously Untreated Patients With Stage B and C Chronic Lymphocytic Leukemia Completed NCT00931645 Phase 3
48 A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects With Refractory Chronic Lymphocytic Leukemia Completed NCT01580228 Phase 3 Dinaciclib;Ofatumumab
49 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia Completed NCT01569295 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo to match idelalisib
50 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia Completed NCT01539512 Phase 3 Idelalisib;Rituximab;Placebo to match idelalisib

Search NIH Clinical Center for Leukemia, Chronic Lymphocytic

Inferred drug relations via UMLS 70 / NDF-RT 51 :


alemtuzumab
Chlorambucil
Cladribine
Cyclophosphamide
etoposide phosphate
fludarabine
Fludarabine phosphate
Ibrutinib
Ifosfamide
Immunoglobulins, Intravenous
mercaptopurine
pegaspargase
Uracil Mustard

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Chronic Lymphocytic cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, lymphocytic, chronic, b-cell

Genetic Tests for Leukemia, Chronic Lymphocytic

Genetic tests related to Leukemia, Chronic Lymphocytic:

# Genetic test Affiliating Genes
1 Chronic Lymphocytic Leukemia 29

Anatomical Context for Leukemia, Chronic Lymphocytic

MalaCards organs/tissues related to Leukemia, Chronic Lymphocytic:

40
Bone Marrow, T Cells, Bone, B Cells, Myeloid, Spleen, Lymph Node
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Chronic Lymphocytic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease

Publications for Leukemia, Chronic Lymphocytic

Articles related to Leukemia, Chronic Lymphocytic:

(show top 50) (show all 17052)
# Title Authors PMID Year
1
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. 57 47 61
16251535 2005
2
miR-15 and miR-16 induce apoptosis by targeting BCL2. 61 47 57
16166262 2005
3
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. 57 61 54
12595313 2003
4
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. 57 61 54
12724482 2003
5
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. 61 6
24869598 2014
6
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. 57 61
23770605 2013
7
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. 57 61
22158541 2011
8
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. 57 61
22150006 2011
9
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. 61 57
21131588 2011
10
Karyotype-specific microRNA signature in chronic lymphocytic leukemia. 61 54 47
19717645 2009
11
Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia. 61 57
17047154 2007
12
HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. 61 57
15931393 2005
13
Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. 57 61
15161669 2004
14
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. 61 57
14973191 2004
15
Cytogenetic findings in familial B-cell chronic lymphocytic leukemia: a report of two cases in a family. 57 61
12781453 2003
16
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. 57 61
12434020 2002
17
Hereditary chronic lymphocytic leukemia: an extended family study and literature review. 61 57
12407690 2002
18
Genomic aberrations and survival in chronic lymphocytic leukemia. 57 61
11136261 2000
19
Linkage analysis for major histocompatibility complex-related genetic susceptibility in familial chronic lymphocytic leukemia. 57 61
11090088 2000
20
Anticipation in familial chronic lymphocytic leukemia. 61 57
10364544 1999
21
Anticipation in familial leukemia. 57 61
8900225 1996
22
Human heavy-chain variable region gene family nonrandomly rearranged in familial chronic lymphocytic leukemia. 61 57
3120193 1987
23
Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia. 61 57
3122218 1987
24
Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. 57 61
6610211 1984
25
Familial chronic lymphocytic leukemia. 61 57
6418939 1983
26
Genetic factors predisposing to chronic lymphocytic leukemia and to autoimmune disease. 61 57
7001171 1980
27
Familial chronic lymphocytic leukemia. Immunologic and cellular characterization. 57 61
818930 1976
28
Familial chronic lymphocytic leukemia. 57 61
4184386 1969
29
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
30
Mutations driving CLL and their evolution in progression and relapse. 57
26466571 2015
31
Non-coding recurrent mutations in chronic lymphocytic leukaemia. 57
26200345 2015
32
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
33
Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia. 47 61
21130495 2011
34
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. 57
21642962 2011
35
Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. 61 47
20566844 2010
36
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. 47 61
20089965 2010
37
miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. 47 61
19692702 2009
38
microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. 61 47
19144983 2009
39
Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. 61 47
19096009 2009
40
MiR-15a and miR-16-1 cluster functions in human leukemia. 47 61
18362358 2008
41
Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. 61 47
17989717 2008
42
Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. 6
18060073 2007
43
The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. 61 47
17707831 2007
44
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. 47 61
17327404 2007
45
Trinucleotide repeat dynamic mutation identifying susceptibility in familial and sporadic chronic lymphocytic leukaemia. 57
17116127 2007
46
Familial cancer associated with a polymorphism in ARLTS1. 57
15843669 2005
47
Predicting Progression--ZAP-70 in CLL. 57
15329421 2004
48
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. 61 47
15284443 2004
49
MicroRNAs: genomics, biogenesis, mechanism, and function. 57
14744438 2004
50
Molecular diagnosis of the hematologic cancers. 57
12724484 2003

Variations for Leukemia, Chronic Lymphocytic

ClinVar genetic disease variations for Leukemia, Chronic Lymphocytic:

6 (show top 50) (show all 104)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TP53 NM_000546.5(TP53):c.332T>G (p.Leu111Arg) SNV Likely pathogenic 376631 rs1057519997 GRCh37: 17:7579355-7579355
GRCh38: 17:7676037-7676037
2 SF3B2 NM_006842.3(SF3B2):c.1997A>C (p.His666Pro) SNV Likely pathogenic 376531 rs1057519959 GRCh37: 11:65830499-65830499
GRCh38: 11:66063028-66063028
3 SF3B1 NM_012433.3(SF3B1):c.1996A>G (p.Lys666Glu) SNV Likely pathogenic 376008 rs754688962 GRCh37: 2:198267361-198267361
GRCh38: 2:197402637-197402637
4 XPO1 NM_003400.4(XPO1):c.1712A>T (p.Glu571Val) SNV Likely pathogenic 376696 rs1057520010 GRCh37: 2:61719471-61719471
GRCh38: 2:61492336-61492336
5 XPO1 NM_003400.4(XPO1):c.1712A>C (p.Glu571Ala) SNV Likely pathogenic 376697 rs1057520010 GRCh37: 2:61719471-61719471
GRCh38: 2:61492336-61492336
6 XPO1 NM_003400.4(XPO1):c.1711G>A (p.Glu571Lys) SNV Likely pathogenic 376695 rs1057520009 GRCh37: 2:61719472-61719472
GRCh38: 2:61492337-61492337
7 SF3B1 NM_012433.3(SF3B1):c.1996A>C (p.Lys666Gln) SNV Likely pathogenic 376532 rs754688962 GRCh37: 2:198267361-198267361
GRCh38: 2:197402637-197402637
8 TP53 NM_000546.5(TP53):c.332T>C (p.Leu111Pro) SNV Likely pathogenic 376630 rs1057519997 GRCh37: 17:7579355-7579355
GRCh38: 17:7676037-7676037
9 BRAF NM_001374258.1(BRAF):c.1511G>A (p.Gly504Glu) SNV Likely pathogenic 13964 rs121913348 GRCh37: 7:140481417-140481417
GRCh38: 7:140781617-140781617
10 FBXW7 NM_001349798.2(FBXW7):c.1514G>A (p.Arg505His) SNV Likely pathogenic 376425 rs1057519896 GRCh37: 4:153247288-153247288
GRCh38: 4:152326136-152326136
11 FBXW7 NM_001349798.2(FBXW7):c.1513C>G (p.Arg505Gly) SNV Likely pathogenic 376423 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
12 FBXW7 NM_001349798.2(FBXW7):c.1514G>T (p.Arg505Leu) SNV Likely pathogenic 376424 rs1057519896 GRCh37: 4:153247288-153247288
GRCh38: 4:152326136-152326136
13 FBXW7 NM_001349798.2(FBXW7):c.1513C>T (p.Arg505Cys) SNV Likely pathogenic 69961 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
14 FBXW7 NM_001349798.2(FBXW7):c.1513C>A (p.Arg505Ser) SNV Likely pathogenic 376426 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
15 TP53 NM_000546.5(TP53):c.842A>T (p.Asp281Val) SNV Likely pathogenic 182968 rs587781525 GRCh37: 17:7577096-7577096
GRCh38: 17:7673778-7673778
16 SF3B1 NM_012433.3(SF3B1):c.2225G>A (p.Gly742Asp) SNV Likely pathogenic 376530 rs755415626 GRCh37: 2:198266611-198266611
GRCh38: 2:197401887-197401887
17 BRAF NM_001374258.1(BRAF):c.1922A>C (p.Lys641Thr) SNV Likely pathogenic 44818 rs397507484 GRCh37: 7:140453133-140453133
GRCh38: 7:140753333-140753333
18 FBXW7 NM_001349798.2(FBXW7):c.1394G>A (p.Arg465His) SNV Likely pathogenic 376415 rs1057519895 GRCh37: 4:153249384-153249384
GRCh38: 4:152328232-152328232
19 TP53 NM_000546.5(TP53):c.578A>G (p.His193Arg) SNV Likely pathogenic 184979 rs786201838 GRCh37: 17:7578271-7578271
GRCh38: 17:7674953-7674953
20 NRAS NM_002524.5(NRAS):c.181C>A (p.Gln61Lys) SNV Likely pathogenic 73058 rs121913254 GRCh37: 1:115256530-115256530
GRCh38: 1:114713909-114713909
21 HRAS , LRRC56 NM_005343.4(HRAS):c.38G>T (p.Gly13Val) SNV Likely pathogenic 180848 rs104894226 GRCh37: 11:534285-534285
GRCh38: 11:534285-534285
22 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr) SNV Likely pathogenic 376585 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
23 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro) SNV Likely pathogenic 280409 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
24 HRAS , LRRC56 NM_005343.4(HRAS):c.37G>C (p.Gly13Arg) SNV Likely pathogenic 35554 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
25 TP53 NM_000546.5(TP53):c.764T>C (p.Ile255Thr) SNV Likely pathogenic 376623 rs876659675 GRCh37: 17:7577517-7577517
GRCh38: 17:7674199-7674199
26 HRAS , LRRC56 NM_005343.4(HRAS):c.181C>G (p.Gln61Glu) SNV Likely pathogenic 376444 rs28933406 GRCh37: 11:533875-533875
GRCh38: 11:533875-533875
27 BRAF NM_004333.6(BRAF):c.1803A>C (p.Lys601Asn) SNV Likely pathogenic 376286 rs121913365 GRCh37: 7:140453132-140453132
GRCh38: 7:140753332-140753332
28 FBXW7 NM_001349798.2(FBXW7):c.1393C>G (p.Arg465Gly) SNV Likely pathogenic 376418 rs867384286 GRCh37: 4:153249385-153249385
GRCh38: 4:152328233-152328233
29 TP53 NM_000546.5(TP53):c.578A>T (p.His193Leu) SNV Likely pathogenic 185822 rs786201838 GRCh37: 17:7578271-7578271
GRCh38: 17:7674953-7674953
30 TP53 NM_000546.5(TP53):c.712T>C (p.Cys238Arg) SNV Likely pathogenic 376576 rs1057519981 GRCh37: 17:7577569-7577569
GRCh38: 17:7674251-7674251
31 TP53 NM_000546.5(TP53):c.584T>G (p.Ile195Ser) SNV Likely pathogenic 376619 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
32 TP53 NM_000546.5(TP53):c.817C>A (p.Arg273Ser) SNV Likely pathogenic 376656 rs121913343 GRCh37: 17:7577121-7577121
GRCh38: 17:7673803-7673803
33 TP53 NM_000546.5(TP53):c.764T>A (p.Ile255Asn) SNV Likely pathogenic 232289 rs876659675 GRCh37: 17:7577517-7577517
GRCh38: 17:7674199-7674199
34 BRAF NM_001374258.1(BRAF):c.1900G>A (p.Asp634Asn) SNV Likely pathogenic 44813 rs397516896 GRCh37: 7:140453155-140453155
GRCh38: 7:140753355-140753355
35 BRAF NM_004333.6(BRAF):c.1780G>C (p.Asp594His) SNV Likely pathogenic 375947 rs397516896 GRCh37: 7:140453155-140453155
GRCh38: 7:140753355-140753355
36 SF3B2 NM_006842.3(SF3B2):c.2099A>G (p.Glu700Gly) SNV Likely pathogenic 376533 rs1057519960 GRCh37: 11:65830884-65830884
GRCh38: 11:66063413-66063413
37 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu) SNV Likely pathogenic 376655 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
38 TP53 NM_000546.5(TP53):c.841G>A (p.Asp281Asn) SNV Likely pathogenic 376586 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
39 HRAS , LRRC56 NM_005343.4(HRAS):c.182A>C (p.Gln61Pro) SNV Likely pathogenic 376322 rs121913233 GRCh37: 11:533874-533874
GRCh38: 11:533874-533874
40 TP53 NM_000546.5(TP53):c.577C>T (p.His193Tyr) SNV Likely pathogenic 230256 rs876658468 GRCh37: 17:7578272-7578272
GRCh38: 17:7674954-7674954
41 TP53 NM_000546.5(TP53):c.742C>G (p.Arg248Gly) SNV Likely pathogenic 376652 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
42 TP53 NM_000546.5(TP53):c.713G>C (p.Cys238Ser) SNV Likely pathogenic 376575 rs730882005 GRCh37: 17:7577568-7577568
GRCh38: 17:7674250-7674250
43 TP53 NM_000546.5(TP53):c.725G>A (p.Cys242Tyr) SNV Likely pathogenic 12354 rs121912655 GRCh37: 17:7577556-7577556
GRCh38: 17:7674238-7674238
44 HRAS , LRRC56 NM_005343.4(HRAS):c.38G>C (p.Gly13Ala) SNV Likely pathogenic 376443 rs104894226 GRCh37: 11:534285-534285
GRCh38: 11:534285-534285
45 TP53 NM_000546.5(TP53):c.641A>T (p.His214Leu) SNV Likely pathogenic 376616 rs1057519992 GRCh37: 17:7578208-7578208
GRCh38: 17:7674890-7674890
46 FBXW7 NM_001349798.2(FBXW7):c.1394G>C (p.Arg465Pro) SNV Likely pathogenic 376416 rs1057519895 GRCh37: 4:153249384-153249384
GRCh38: 4:152328232-152328232
47 TP53 NM_000546.5(TP53):c.724T>G (p.Cys242Gly) SNV Likely pathogenic 376581 rs1057519982 GRCh37: 17:7577557-7577557
GRCh38: 17:7674239-7674239
48 TP53 NM_000546.6(TP53):c.841G>C SNV Likely pathogenic 376588 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
49 TP53 NM_000546.5(TP53):c.584T>C (p.Ile195Thr) SNV Likely pathogenic 216077 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
50 TP53 NM_000546.5(TP53):c.713G>A (p.Cys238Tyr) SNV Likely pathogenic 182935 rs730882005 GRCh37: 17:7577568-7577568
GRCh38: 17:7674250-7674250

Copy number variations for Leukemia, Chronic Lymphocytic from CNVD:

7 (show top 50) (show all 1219)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14042 1 103366560 104230405 Loss Chronic lymphocytic leukemia
2 14895 1 110954839 111582296 Loss Chronic lymphocytic leukemia
3 14947 1 111421057 111642223 Loss Chronic lymphocytic leukemia
4 15456 1 115719205 117399077 Loss Chronic lymphocytic leukemia
5 17206 1 141510591 145121245 Deletion Chronic lymphocytic leukemia
6 17207 1 141510591 145121245 Loss Chronic lymphocytic leukemia
7 18527 1 146265358 148164994 Gain Chronic lymphocytic leukemia
8 19758 1 151208615 155645185 Gain Chronic lymphocytic leukemia
9 20025 1 152611898 157344161 Loss Chronic lymphocytic leukemia
10 21378 1 158336749 159355008 Loss Chronic lymphocytic leukemia
11 21384 1 158391645 159433573 Loss Chronic lymphocytic leukemia
12 21385 1 158391645 189498990 Loss Chronic lymphocytic leukemia
13 23023 1 170758115 170759115 Loss Chronic lymphocytic leukemia
14 23030 1 170822660 170823660 Gain Chronic lymphocytic leukemia
15 23626 1 172107770 172108770 Gain Chronic lymphocytic leukemia
16 24171 1 176708253 177307399 Gain Chronic lymphocytic leukemia
17 25274 1 186459864 186720923 Loss Chronic lymphocytic leukemia
18 25359 1 187890295 188217703 Loss Chronic lymphocytic leukemia
19 25435 1 189143434 189363313 Gain Chronic lymphocytic leukemia
20 25473 1 189804292 192389810 Gain Chronic lymphocytic leukemia
21 25685 1 193314169 193528753 Gain Chronic lymphocytic leukemia
22 26789 1 202768030 203457313 Loss Chronic lymphocytic leukemia
23 26818 1 203067017 205298659 Loss Chronic lymphocytic leukemia
24 26975 1 204424298 206588789 Loss Chronic lymphocytic leukemia
25 28076 1 218313329 220732423 Loss Chronic lymphocytic leukemia
26 28130 1 218942571 219164038 Loss Chronic lymphocytic leukemia
27 28133 1 218959043 244561923 Loss Chronic lymphocytic leukemia
28 28265 1 220678511 222112407 Gain Chronic lymphocytic leukemia
29 28321 1 221304071 221582122 Gain Chronic lymphocytic leukemia
30 28577 1 223594083 225234079 Loss Chronic lymphocytic leukemia
31 28643 1 224353010 225571533 Loss Chronic lymphocytic leukemia
32 28702 1 224857883 233411748 Loss Chronic lymphocytic leukemia
33 29066 1 227299711 227518155 Loss Chronic lymphocytic leukemia
34 29113 1 227696842 233631743 Loss Chronic lymphocytic leukemia
35 29265 1 229664393 229947546 Gain Chronic lymphocytic leukemia
36 29501 1 232707626 233302391 Loss Chronic lymphocytic leukemia
37 31053 1 24943712 26054939 Loss Chronic lymphocytic leukemia
38 31193 1 25985121 29490451 Deletion Chronic lymphocytic leukemia
39 31425 1 27504484 28494376 Loss Chronic lymphocytic leukemia
40 32443 1 36783544 38823237 Loss Chronic lymphocytic leukemia
41 33495 1 45606989 46307302 Gain Chronic lymphocytic leukemia
42 34016 1 51545765 53346467 Loss Chronic lymphocytic leukemia
43 34255 1 54029769 55100800 Loss Chronic lymphocytic leukemia
44 34911 1 57712092 58034742 Gain Chronic lymphocytic leukemia
45 35379 1 62697088 63142732 Loss Chronic lymphocytic leukemia
46 35406 1 63335974 63596958 Gain Chronic lymphocytic leukemia
47 35407 1 63335974 63641668 Gain Chronic lymphocytic leukemia
48 36497 1 76364563 76710672 Loss Chronic lymphocytic leukemia
49 36890 1 82341866 82576806 Loss Chronic lymphocytic leukemia
50 36895 1 82581235 82812961 Loss Chronic lymphocytic leukemia

Expression for Leukemia, Chronic Lymphocytic

Search GEO for disease gene expression data for Leukemia, Chronic Lymphocytic.

Pathways for Leukemia, Chronic Lymphocytic

GO Terms for Leukemia, Chronic Lymphocytic

Cellular components related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 MIR424 MIR29A MIR181A2 MIR16-1 MIR15A MIR143
2 extracellular vesicle GO:1903561 9.1 MIR34A MIR29A MIR16-1 MIR15A MIR107 MIR106B

Biological processes related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.97 TP53 MIR29A MIR16-1 MIR15A ATM
2 negative regulation of gene expression GO:0010629 9.91 TP53 MIR34A MIR29A MIR181A2 MIR106B
3 gene silencing by miRNA GO:0035195 9.85 MIR424 MIR34A MIR29A MIR181A2 MIR16-1 MIR15A
4 negative regulation of inflammatory response GO:0050728 9.8 MIR181A2 MIR16-1 MIR15A MIR145
5 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.78 MIR29A MIR16-1 MIR15A
6 negative regulation of protein kinase B signaling GO:0051898 9.77 MIR34A MIR29A MIR145
7 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.76 MIR424 MIR16-1 MIR15A
8 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.72 MIR424 MIR34A MIR15A
9 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.7 TP53 MIR16-1 MIR15A
10 replicative senescence GO:0090399 9.64 TP53 ATM
11 negative regulation of glucose import GO:0046325 9.64 MIR143 MIR107
12 positive regulation of connective tissue replacement GO:1905205 9.63 MIR34A MIR16-1
13 negative regulation of telomerase activity GO:0051974 9.63 TP53 POT1
14 angiotensin-activated signaling pathway GO:0038166 9.62 MIR145 MIR143
15 mitotic G1 DNA damage checkpoint GO:0031571 9.62 TP53 CCND1
16 negative regulation of amyloid precursor protein catabolic process GO:1902992 9.61 MIR29A MIR107
17 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.61 MIR424 MIR16-1 MIR15A
18 regulation of telomere maintenance via telomerase GO:0032210 9.59 POT1 ATM
19 negative regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000545 9.57 MIR424 MIR16-1
20 aorta smooth muscle tissue morphogenesis GO:0060414 9.56 MIR145 MIR143
21 negative regulation of vascular endothelial growth factor production GO:1904046 9.56 MIR34A MIR16-1 MIR15A MIR107
22 regulation of phenotypic switching GO:1900239 9.54 MIR145 MIR143
23 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.54 MIR424 MIR34A MIR15A
24 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.5 TP53 MIR34A MIR16-1
25 miRNA mediated inhibition of translation GO:0035278 9.5 MIR29A MIR181A2 MIR16-1 MIR15A MIR145 MIR107
26 negative regulation of endothelial cell chemotaxis to vascular endothelial growth factor GO:1904858 9.48 MIR424 MIR16-1
27 negative regulation of cell chemotaxis to fibroblast growth factor GO:1904848 9.46 MIR16-1 MIR15A
28 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.4 MIR145 MIR143
29 negative regulation of angiogenesis GO:0016525 9.23 MIR424 MIR34A MIR29A MIR16-1 MIR15A MIR145

Molecular functions related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.65 MIR424 MIR34A MIR29A MIR181A2 MIR16-1 MIR15A
2 histone deacetylase binding GO:0042826 9.33 TP53 IKZF3 CCND1
3 mRNA 3'-UTR binding GO:0003730 9.32 TP53 MIR424 MIR34A MIR29A MIR181A2 MIR16-1

Sources for Leukemia, Chronic Lymphocytic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....